Rezolute, Inc.

Today we provided financial results and a business update for fiscal Q4 2025. Learn more about recent progress in our two Phase 3 trials as we advance our novel therapy, ersodetug, for the potential treatment of hypoglycemia caused by all forms of HI: http://bit.ly/48khC3k #hyperinsulinism #raredisease

Today we announced alignment with FDA on a streamlined design for the ongoing Phase 3 trial of ersodetug in patients with tumor hyperinsulinism (HI). This is an incredible outcome, representative of the Agency's recognition of ersodetug as a potential universal treatment for multiple forms of HI, and the high unmet need in this patient population. Learn more: http://bit.ly/4mM7qVV #RareDisease #Hyperinsulinism #TumorHI #DrugDevelopment

Rezolute will participate in several upcoming investor conferences to discuss progress across our pipeline in the treatment of #hyperinsulinism. Contact your Cantor Fitzgerald, H.C. Wainwright & Co., LLC and Morgan Stanley representatives to request a meeting with management. http://bit.ly/45So2np

Proud to take part in this past weekend's 16th Annual Kongenitaler Hyperinsulinismus, e.V. meeting in Berlin, Germany. The Association continues to empower families facing #congenitalhyperinsulinism (cHI) with education, story telling, exciting activities and support across every stage of life. We’re excited to keep working together to increase awareness and a better understanding of cHI. #RareDisease #CHI #PatientAdvocacy #Research

👏 We applaud Congenital Hyperinsulinism International, the authors, and—most importantly—the patients and families—for their groundbreaking study on the real-world experience of diazoxide in congenital hyperinsulinism. By capturing the community’s voice in an innovative and scientific way, this publication shines a light on the daily challenges and side effects often overlooked, reinforcing the urgent call for safer, more effective treatments.  Congratulations to Tai Pasquini, Kristen Rohli, Fiona Almeida, Indraneel Banerjee, Dastamani Antonia, Diva De Leon-Crutchlow, Lauren Lopez, PhD, Paul Thornton, Julie Raskin on this major milestone! http://bit.ly/46257Xr #RZLT #CHI #Hyperinsulinism #UnmetNeeds #RareDisease #Diazoxide

We are thrilled to welcome Sunil Karnawat to our team as Chief Commercial Officer! With over 25 years of experience in global commercialization of biopharmaceuticals and medical devices, Sunil’s leadership will be instrumental as we build a world-class organization: http://bit.ly/4fMknfG #biotech #raredisease #hyperinsulinism #hypoglycemia

🌍💙 Grateful to Connect at the UK Congenital HI Family Conference  A heartfelt thank you to the organizers and families who made this past weekend’s Children’s Hyperinsulinism Charity Family Conference in the UK such an inspiring and meaningful experience.  It was a privilege to connect with patients, caregivers, clinicians, and researchers who are united in advancing care and building community for those affected by #cHI. Your stories and resilience continue to inspire our team.   We appreciate the ongoing collaboration and making a lasting impact for all those living with #hyperinsulinism!  #CongenitalHI #RareDisease #ChildrensHyperinsulinismUK  #RZLTCaresAboutRare 

🌞 sunRIZE Preliminary Demographics and Baseline Characteristics☀️ 📈#ICYMI: we presented "Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunrize) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress" at ENDO 2025. Comparable to what we witnessed in the Phase 2 RIZE study, this data continues to support our commitment to advancing care for patients living with congenital hyperinsulinism and other rare endocrine disorders.  📎 View the full poster here: http://bit.ly/416Pdt5 🙏Thank you to all who stopped by and engaged with us at #ENDO2025! #Phase3 #sunRIZE #Hyperinsulinism #RareDisease #PediatricEndocrinology #CongenitalHI #RZLT 

Rezolute management will participate in the upcoming BTIG Virtual Biotechnology Conference taking place next week to discuss progress across our programs in treating #hyperinsulinism. Investors interested in scheduling a meeting should contact their BTIG representative. http://bit.ly/3IMG2b3

Proud to present "Preliminary Patient Demographics and Baseline Characteristics From a Phase 3 Study (sunRIZE) of Ersodetug for Hypoglycemia Due to Congenital Hyperinsulinism: Trial in Progress" today at #ENDO2025. View the full poster here: http://bit.ly/44x4GF6 #raredisease #hyperinsulinism #biotech